RCUS — Arcus Biosciences, Inc.
$17.43
$-0.34 (-1.91%)
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody.
Market Cap
$2.51B
Forward P/E
-5.6x
52-Week Range
N/A
RCUS Price History
Revenue vs. Net Income
$247M
Revenue · FY2025
Annual. Net margin is shown under each year.
Free Cash Flow
-$484M
FCF · FY2025
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
-38.0%
ROCE · FY2025
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
2.2x
Assets ÷ liabilities · FY2025
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
0.8%
CapEx · FY2025
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
+19.2%
Dilution · FY2025
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
